Wooden blocks spelling “AML” with a stethoscope beside them, representing Syndax Pharmaceuticals’ focus on Acute Myeloid Leukemia treatment.
#SNDX presented new data at #EHA2025 showing nearly half of patients with tough-to-treat mNPM1 AML responded to Revuforj. Median survival for responders hit 23.3 months. FDA decision expected later this year.
#Syndax
prismmarketview.com/syndax-share...